The global healthcare specialty enzymes market is anticipated to reach market size of around US$ 8,000 Mn by 2027 and is anticipated to grow at a CAGR of around 9% in terms of revenue during the forecast period 2020 - 2027.
Protein macromolecules are enzymes acting as a biocatalyst that facilitate reaction rates, without altering chemistry. Many chemical reactions, most of them controlled by enzymes, take place in all living organisms. Depletion of the body's enzyme capacity often results in pain, indigestion, swelling, immune deficit and many more. The use of traditional medicinal products only provides temporary relief, while enzymes are used by binding multiple target molecules to the target site to reduce the underlying cause of health problem. Valuable medicinal and industrial application is given to specialty enzymes.
Included in the market for the health care specialist enzymes are such reasons as increased occurrence of metabolic disorders related to the abnormality of the enzymes and incorporations of enzymes as indicators of diseases during clinical exams. In addition, increased demand for pharmaceuticals, substantial financial support for the field of biotechnology and breakthroughs in enzyme engineering & green chemicals will further fuel market patterns over the next decade. The quickly developing regional market and growing clinical in vitro diagnostics would also provide the health-related enzymes sector with new growth opportunities. In addition, the introduction of DNA sequencing techniques and dynamic molecular diagnostics will further intensify the development of business development for healthcare specialty in the coming years. Factories such as growing demand for medicine prevention. Increased occurrence of enzyme abnormality-related metabolic disorders and the integration of enzymes as disease measures in clinical examinations contribute to market growth.
The demand of health specialty enzymes was led by North America and represented the biggest share of revenue in 2019 by 38.2%. The country has the main industry contributor to the high penetration of enzyme technology of more than US$ 900 Mn. Furthermore, the expanding sales and distributors in the area are likely to increase the need of the region's health specialty enzymes. The involvement of key players in the U.S. has provided easy, diagnostic and analysis access to emerging enzymes. Creative enzymes, for example, located in the US; provide enzymes which are useful for medical research, chemical and environmental safety. In addition, the company manufactures cell biology, chemical manufacturing and antibody testing enzymes. In Asia-Pacific, a broad consumption base for diagnostic consumables and reagents is expected to increase the specialty enzyme demand in the region.
DuPont Nutrition & Biosciences has launched its leading industry portfolio OPTIMASE. This portfolio includes biological enzymes used for medical device washing. The food selection aims to achieve good efficiency and reduce the ingredients that maintain the enzymes and thus save room and costs.
The company's enzyme supply has been signed by Roche Holding (Switzerland) and Codexis (U.S.). EvoT4 DNA Ligase will be supplied to Roche with Codexis. EvoT4 is a molecular diagnostic enzyme with a high degree of efficiency.
BASF (Germany), the leader in biotechnological science, entered into a cooperation agreement with Conagen (US). Conagen has high research and development potential for fermented ingredients. This decision would encourage BASF to supply one of the most requested fragrance ingredients, the natural vanillin, on the market.
In East Africa, its presence in Novozymes (Denmark) has increased. The organization was thus able to satisfy the customers ' expectations for the region's enzyme products.
In Framingham, Massachusetts, Sanofi (France) opened the first digitally activated production plant. The new factory has the technology to connect production process with research and development. The promotion of new drugs is also increased.
The prominent players in the healthcare specialty enzymes market include Codexis, Novozymes, Affymetrix, Amicogen, Amano Enzymes, Advanced Enzymes Technologies, Biocatalysts, Roche Custombiotech, S Bbi Solutions, ekisui Diagnostics, Hoffmann-la Roche, Merck, Amano Enzymes, and others.
The global healthcare specialty enzymes market is segmented as below:
Healthcare Specialty Enzymes Market By Type
Healthcare Specialty Enzymes Market By Source
Healthcare Specialty Enzymes Market By Application
Research & Biotechnology
Healthcare Specialty Enzymes Market By Geography
Middle East & Africa
The market for healthcare specialty enzymes is expected to reach a market value of around US$ 8,000 Mn by 2027.
The healthcare specialty enzymes market is expected to grow at a CAGR of around 9% from 2020 to 2027.
The pharmaceuticals are the leading segment by application in the healthcare specialty enzymes market.
The healthcare specialty enzymes market is anticipated to grow in the forecast period owing to key factors such as the elderly application fuels the pharmaceutical diagnostic enzymes demand, strong investments in the biotech sector pulls the demand for enzymes, advancement in enzyme engineering & green chemistry, and rapid growth in the pharmaceutical industry.
Codexis, Novozymes, Affymetrix, Amicogen, Amano Enzymes, Advanced Enzymes Technologies, Biocatalysts, Roche Custombiotech, S Bbi Solutions, ekisui Diagnostics, Hoffmann-la Roche, Merck, Amano Enzymes, and others are the prominent players in the market.
North America held the highest market share in the healthcare specialty enzymes market.
Asia Pacific is expected to be the fastest growing market over the forecast period.